Drugs offer new hope for patients with CML who are resistant to imatinib.
作者信息
Oestreicher Pamela
出版信息
ONS Connect. 2007 Jul;22(7):20-1.
PMID:17694781
Abstract
摘要
相似文献
1
Drugs offer new hope for patients with CML who are resistant to imatinib.
ONS Connect. 2007 Jul;22(7):20-1.
2
Management of the new patient with CML in chronic phase.
Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0.
3
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Expert Opin Pharmacother. 2007 Dec;8(18):3257-64. doi: 10.1517/14656566.8.18.3257.
4
Looking beyond imatinib: next line of targeted drugs for CML shows promise.
JAMA. 2006 Jan 25;295(4):369-70. doi: 10.1001/jama.295.4.369.
5
[Treatment of imatinib-intolerant or -resistant CML patients].
Nihon Rinsho. 2012 Apr;70 Suppl 2:304-8.
6
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Clin J Oncol Nurs. 2007 Feb;11(1):125-9. doi: 10.1188/07.CJON.125-129.
7
Dasatinib is effective in imatinib-resistant CML.
Lancet Oncol. 2007 Apr;8(4):286. doi: 10.1016/s1470-2045(07)70088-8.
8
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Leukemia. 2012 Jan;26(1):172-7. doi: 10.1038/leu.2011.187. Epub 2011 Aug 5.
9
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21. doi: 10.1586/erp.09.1.
10
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.
Zotero 插件